Form 4: Bristol-Myers Squibb Executive Lynelle Hoch Reports Stock Transactions

Lynelle Hoch, President of Cell Therapy Org. at Bristol-Myers Squibb, reports the vesting and acquisition of common stock and market share units, as well as shares withheld for tax payments.

Summary

• On March 10, 2025, Lynelle Hoch, President of Cell Therapy Org. at Bristol-Myers Squibb, reported transactions involving the company's common stock and derivative securities.
• These transactions include the vesting of market share units and performance shares, resulting in the acquisition of common stock.
• Shares were also withheld for payment of taxes upon the vesting of awards.
• The reported transactions changed the amount of securities beneficially owned by Hoch.
• The price of common stock at the time of withholding was $63.11.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing executive stock transactions, which is neither particularly positive nor negative. The vesting of awards suggests that performance targets were met, which is mildly positive.

Positives

• The vesting of market share units and performance shares indicates that certain performance metrics were likely met, triggering the vesting events.

Future Outlook

Future vesting of market share units and performance shares are subject to performance conditions and board certification.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's future prospects.

Comparison to Industry Standards

• Executive compensation packages at large pharmaceutical companies like Bristol-Myers Squibb typically include a mix of salary, stock options, restricted stock units (RSUs), and performance-based awards.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize similar long-term incentive plans to align executive compensation with shareholder value creation.
• The vesting schedules and performance metrics associated with these awards are often benchmarked against industry peers to ensure competitiveness and effectiveness.

Stakeholder Impact

• The vesting of executive stock awards can have a minor dilutive effect on existing shareholders.
• The transactions reflect the company's compensation policies and their impact on executive ownership.

Key Dates